This article is more than 5 years old. Information may no longer be current.
Arhalofenate, febuxostat seen as safe, effective for patients with hyperuricemia linked with gout
Click Here to Manage Email Alerts
All 32 patients who had hyperuricemia associated with gout treated with combination therapy of arhalofenate and febuxostat reached their target serum uric acid level of less than 6 mg/dL, according to results of a recently published study.
Alexandra S. Steinberg, MD, PhD, at CymaBay Therapeutics Inc. in California, and colleagues performed a phase 2 trial in 32 patients with gout who were split evenly into two treatment groups. The first group received 2 weeks of 600-mg arhalofenate (ARH) followed by 1 week of co-administration with 80 mg of febuxostat (FBX), then 1 week of co-administration with 40 mg of FBX and then 2 weeks of 40-mg FBX monotherapy. The second group received 2 weeks of 800-mg ARH followed by 1 week of co-administration with 40 mg of FBX, then 1 week of co-administration with 80 mg of FBX and then 2 weeks of 80-mg FBX monotherapy. Researchers assessed serum uric acid level (SUA), fractional excretion uric acid (FEUA) and plasma oxypruines. For the second group, they determined the pharmacokinetics of FBX and ARH both alone and in combination.
Researchers found baseline SUA was 9.4 mg/dL for the first group and 9.2 mg/dL for the second group. Baseline FEUA was between 3.5% and 4.6%. The largest SUA decrease, which was 63%, occurred in the second group during the 1 week combination therapy of 800-mg ARH with 80-mg FBX, with all patients below their SUA target of 6 mg/dL and 93% below 5 mg/dL. ARH co-administration did not affect FBX-increased oxypurines. – by Will Offit
Disclosure: The researchers report no relevant financial disclosures.
Click Here to Manage Email Alerts